哺乳动物细胞自噬关键节点及相关药物的研究进展

doi:10.12092/j.issn.1009-2501.2018.02.017

摘要/Abstract

摘要：

自噬是一种在压力条件下被激活的可降解和循环利用大分子和细胞器的代谢过程。自噬对维持细胞内环境的稳态有重要作用，并与许多疾病尤其是肿瘤的发生发展息息相关，这使得以调控自噬为靶标的新药开发及临床治疗研究越来越受到瞩目。但是，自噬过程的调控机制非常复杂，本文就目前受到关注的涉及自噬信号通路的mTOR、ULK、Beclin-1、Atg12连接系统、LC3脂质化连接系统、p62等关键节点及相关药物研究进展做一介绍。

关键词: 自噬, 靶点, 信号通路, 药物研发

Abstract:

Autophagy is a catabolic process for the degradation and recycling of macromolecules and organelles, which is activated during stress conditions. It plays an important role in maintain a homeostasis in the cell, and is closely related to many diseases, especially the development of tumor, which makes researchers pay more attention on control autophagy as a target of new drug development and clinical application. However, the mechanism of autophagy process is very complicated. This article reviews the research progress of crucial targets mTOR, ULK, Beclin 1, Atg12 connection system, LC3 lipid connection system and p62/SQSM1, which are involved in autophagy signaling pathways and its related drugs.

Key words: autophagy, target, signaling pathway, drug development

中图分类号:

R966

王欣，陈宝强，李红玉. 哺乳动物细胞自噬关键节点及相关药物的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(2): 205-210.

WANG Xin, CHEN Baoqiang, LI Hongyu. Research progress of the key targets of autophagy and related drugs in mammalian cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 205-210.

参考文献

［1］Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease［J］. Annu Rev Pathol, 2008, 3: 427-455.
［2］Murrow L, Debnath J. Autophagy as a stress-response and quality-control mechanism: implications for cell injury and human disease［J］. Annu Rev Pathol, 2013, 8:105-137.
［3］Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion ［J］. Nature, 2008,451(7182): 1069-1075.
［4］Yang Q, Guan KL. Expanding mTOR signaling［J］. Cell Res, 2007,17(8): 666-681.
［5］李乐兴,戴汉川.细胞自噬调控的分子机制研究进展［J］.中国细胞生物学学报,2015,37(2):263-270.
［6］Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation［J］. J Clin Invest, 2015,125(1): 25-32.
［7］Wu YT, Tan HL, Shui G, et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase［J］. J Biol Chem, 2010, 285(14): 10850-10861.
［8］F OF, Rusten TE, Stenmark H. Phosphoinositide 3-kinases as accelerators and brakes of autophagy［J］. FEBS J, 2013, 280(24): 6322-6337.
［9］Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease［J］. Annu Rev Pharmacol Toxicol, 2013, 53: 89-106.
［10］Dinner S, Platanias LC. Targeting the mTOR Pathway in Leukemia［J］. J Cell Biochem, 2016, 117(8): 1745-1752.
［11］Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma［J］. Oncotarget, 2016, 7(22): 33440-33450.
［12］Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment［J］. Cancer Metastasis Rev, 2016,35(4):515-524.
［13］Chen R, Duan J, Li L, et al. mTOR promotes pituitary tumor development through activation of PTTG1［J］. Oncogene, 2017, 36(7):979-988.
［14］Rodon J, Brana I, Siu LL, et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors［J］. Invest New Drugs, 2014,32(4): 670-681.
［15］Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling［J］. Mol Cancer Ther, 2004,3(7):763-772.
［16］Civallero M, Cosenza M, Pozzi S, et al. Activity of BKM120 and BEZ235 against lymphoma cells［J］. Biomed Res Int, 2015: 870918-870930.
［17］Pal SK,Reckamp K,Yu H,et al.Akt inhibitors in clinical development for the treatment of cancer［J］.Expert Opin Investig Drugs,2010,19(11):1355-1366.
［18］Zhao YY, Tian Y, Zhang J, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo［J］. Drug Des Devel Ther, 2014, 8: 1827-1837.
［19］Cani A, Simioni C, Martelli AM, et al. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia［J］. Oncotarget, 2015, 6(9): 6597-6610.
［20］Song X, Kim SY, Zhang L, et al. Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer［J］. Cell Death Dis, 2014, 5: e1504.
［21］Feldman ME, Shokat KM. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs)［J］. Curr Top Microbiol Immunol, 2010, 347: 241-262.
［22］Suangtamai T, Tanyong DI. Diallyl disulfide induces apoptosis and autophagy via mTOR pathway in myeloid leukemic cell line［J］. Tumour Biol, 2016, 37(8):10993-10999.
［23］Hu M, Huang H, Zhao R, et al. AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma［J］. Oncol Rep, 2014, 31(2):649-656.
［24］Yongxi T, Haijun H, Jiaping Z, et al. Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo［J］. Biochem Biophys Res Commun, 2015, 465(3): 494-500.
［25］Rodrik-Outmezguine VS, Okaniwa M, Yao Z, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor［J］. Nature, 2016, 534(7606): 272-276.
［26］Mazan-Mamczarz K, Peroutka RJ, Steinhardt JJ, et al. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma［J］. Cell Commun Signal, 2015, 13: 1-15.
［27］Ghosh J,Kapur R.Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia［J］.Exp Hematol,2017,50:13-21.
［28］Chan EY, Longatti A, McKnight NC, et al. Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism［J］. Mol Cell Biol, 2009, 29(1):157-171.
［29］Hara T, Takamura A, Kishi C, et al. FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells［J］. J Cell Biol, 2008, 181(3):497-510.
［30］Nishimura T, Kaizuka T, Cadwell K, et al. FIP200 regulates targeting of Atg16L1 to the isolation membrane［J］. EMBO Rep, 2013, 14(3): 284-291.
［31］付婉, 董笛, 赵颖. 自噬的相关分子机制［J］. 中国生物化学与分子生物学报, 2017, 33(5): 448-455.
［32］Jung CH,Jun CB,Ro SH,et al.ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery［J］.Mol Biol Cell,2009,20(7):1992-2003.
［33］Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1［J］. Nat Cell Biol, 2011,13(2): 132-141.
［34］ Pasquier B, Autophagy inhibitors［J］. Cell Mol Life Sci, 2016, 73(5): 985-1001.
［35］Petherick KJ,Conway OJ,Mpamhanga C,et al.Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin(mTOR)-dependent autophagy［J］.J Biol Chem,2015,290(18):11376-11383.
［36］Egan DF, Chun MG, Vamos M, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates ［J］. Mol Cell, 2015, 59(2): 285-297.
［37］Mei Y,Glover K,Su M,et al.Conformational flexibility of BECN1:Essential to its key role in autophagy and beyond［J］.Protein Sci,2016,25(10):1767-1785.
［38］Fu LL, Cheng Y, Liu B. Beclin-1: autophagic regulator and therapeutic target in cancer［J］. Int J Biochem Cell Biol, 2013, 45(5): 921-924.
［39］Sinha S, Levine B. The autophagy effector Beclin 1: a novel BH3-only protein［J］. Oncogene, 2008, 27( Suppl 1): S137-148.
［40］Sun Q,Fan W,Chen K,et al.Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase［J］.Proc Natl Acad Sci USA,2008,105(49):19211-19216.
［41］Liang C, Feng P, Ku B, et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG［J］. Nat Cell Biol, 2006, 8(7): 688-699.
［42］Cao Y, Klionsky DJ. Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein［J］. Cell Res, 2007,17(10): 839-849.
［43］Wirawan E, Lippens S, Vanden Berghe T, et al. Beclin1: a role in membrane dynamics and beyond［J］. Autophagy, 2012, 8(1): 6-17.
［44］Sun Q, Fang W, Zhong Q. Regulation of Beclin 1 in autophagy［J］. Autophagy, 2009,5(5): 713-716.
［45］Liang C, Feng P, Ku B, et al. UVRAG: A new player in autophagy and tumor cell growth. Autophagy, 2014, 3(1): 69-71.
［46］Liang C, Lee JS, Inn KS, et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking［J］. Nat Cell Biol, 2008, 10(7): 776-787.
［47］Lindqvist LM, Heinlein M, Huang DC, et al. Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak［J］. Proc Natl Acad Sci U S A, 2014, 111(23): 8512-8517.
［48］ Jung YY,Lee YK,Koo JS.The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer［J］.Expert Opin Ther Targets,2016,20(2):167-178.
［49］Malik SA, Orhon I, Morselli E, et al. BH3 mimetics activate multiple pro-autophagic pathways［J］. Oncogene, 2011,30(37): 3918-3929.
［50］Hoyer-Hansen M, Bastholm L, Mathiasen IS, et al. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death［J］. Cell Death Differ, 2005, 12(10): 1297-1309.
［51］Lian J, Wu X, He F, et al. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum［J］. Cell Death and Differentiation, 2010,18(1): 60-71.
［52］Tang B, Dong X, Wei Z, et al. Enhanced autophagy by everolimus contributes to the antirestenotic mechanisms in vascular smooth muscle cells［J］. J Vasc Res, 2014, 51(4):259-268.
［53］Kim DE, Kim Y, Cho DH, et al. Raloxifene induces autophagy-dependent cell death in breast cancer cells via the activation of AMP-activated protein kinase［J］. Mol Cells, 2015, 38(2): 138-144.
［54］Shao S, Li S, Qin Y, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia［J］. Int J Oncol, 2014,44(5):1661-1668.
［55］Vicencio JM, Ortiz C, Criollo A, et al. The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1［J］. Cell Death Differ, 2009, 16(7):1006-1017.
［56］Tanida I, Autophagy basics［J］. Microbiol Immunol, 2011, 55(1): 1-11.
［57］Shibutani ST, Yoshimori T. A current perspective of autophagosome biogenesis［J］. Cell Res, 2014, 24(1):58-68.
［58］Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing［J］. Embo j, 2000, 19(21): 5720-5728.
［59］Fujita N, Itoh T, Omori H, et al. The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy［J］. Mol Biol Cell, 2008, 19(5): 2092-2100.
［60］Sakoh-Nakatogawa M, Matoba K, Asai E, et al. Atg12-Atg5 conjugate enhances E2 activity of Atg3 by rearranging its catalytic site［J］. Nat Struct Mol Biol, 2013, 20(4):433-439.
［61］Dooley HC, Razi M, Polson HE, et al. WIPI2 links LC3 conjugation with PI3P, autophagosome formation, and pathogen clearance by recruiting Atg12-5-16L1［J］. Mol Cell, 2014, 55(2):238-252.
［62］Martinez J, Cunha LD, Park S, et al. Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells［J］. Nature, 2016, 533(7601): 115-119.
［63］Lin X, Li S, Zhao Y, et al. Interaction domains of p62: a bridge between p62 and selective autophagy［J］. DNA Cell Biol, 2013,32(5): 220-227.
［64］Lippai M, Low P.The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy［J］. Biomed Res Int, 2014, 2014: 832704-832715.
［65］Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy［J］. J Biol Chem, 2007, 282(33): 24131-24145.
［66］Duran A, Amanchy R, Linares JF, et al. p62 is a key regulator of nutrient sensing in the mTORC1 pathway［J］. Mol Cell, 2011, 44(1): 134-146.
［67］Linares JF, Duran A, Reina-Campos M, et al. Amino Acid Activation of mTORC1 by a PB1-Domain-Driven Kinase Complex Cascade［J］. Cell Rep, 2015, 12(8): 1339-1352.

[1]	王洁, 李龙, 陈凤, 刘胜菲. 核因子E2相关因子2在肺纤维化中的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(9): 1067-1072.
[2]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[3]	秦文秀, 许军峰, 杨婷, 王坪霏. 丹参酮IIA治疗缺血性脑卒中后神经损伤的信号通路研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 705-713.
[4]	封壮壮, 宋瑞平, 豆鹏程, 陈心怡, 左娇娇, 舒劲. 基于mTOR/Beclin1/LC3信号轴探讨制萎扶胃丸对胃癌前病变大鼠胃窦组织自噬的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 361-370.
[5]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[6]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[7]	马广立, 张菁. 定量药理学在疫苗研发中应用的概述与展望[J]. 中国临床药理学与治疗学, 2023, 28(3): 315-322.
[8]	侯小煜, 冷玉芳, 曹雪芬, 吕兴娇, 韩晓霞, Janvier NIBARUTA, 刘永强. 五味子乙素减轻小鼠肠缺血再灌注损伤的网络药理学分析及实验验证[J]. 中国临床药理学与治疗学, 2023, 28(2): 147-154.
[9]	白佳, 杨虹, 李玲玲, 张洋洋, 杨莹, 吕海宏. 维生素D通过线粒体/自噬途径影响糖尿病神经病变机制的研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 214-219.
[10]	王洁, 李龙, 陈凤, 刘胜菲. 二甲双胍干预肺纤维化发病机制的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 235-240.
[11]	朱瑞芳, 郭东凯, 智慧, 江翊国, 张悦翎, 钱晓萍, 季士亮. ROS-NF-κB-p38MAPK通路探索榄香烯联合硼替佐米抗多发性骨髓瘤的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1219-1226.
[12]	李菲, 丁慧琴, 陈梦静. 异莲心碱激活ERK信号通路诱导肺癌PC9细胞自噬的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1235-1240.
[13]	陈玉林, 蒋虎刚, 王新强, 刘凯, 李应东, 安涛, 赵信科. 基于网络药理学和分子对接探讨芪参益心颗粒治疗射血分数保留型心力衰竭的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(10): 1081-1092.
[14]	张晶玉, 王一涵, 李珺, 金平, 申希平, 王迎斌, 刘婕婷. 自噬促进大鼠肠缺血再灌注损伤的细胞铁死亡[J]. 中国临床药理学与治疗学, 2023, 28(1): 36-41.
[15]	黄会珍, 韩磊, 林晓冬, 陈磊. 胰腺炎发病机制相关信号通路研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 109-113.